{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:55:55Z","timestamp":1790812555588,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["E2A-24-1145198"],"award-info":[{"award-number":["E2A-24-1145198"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["RO1 AG059717"],"award-info":[{"award-number":["RO1 AG059717"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    SHIP1-deficient mice develop severe, transmural Crohn\u2019s-like ileitis and die prematurely. Recent analysis of a human Crohn\u2019s disease (CD) cohort revealed a significant subset of patients have severely reduced levels of SHIP1 expression suggesting SHIP1 deficiency leads to CD in both rodents and humans. The mucosal inflammatory disease that causes the premature death of SHIP1\n                    <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    mice is a consequence of the requirement of SHIP1 expression for the survival of effector T cells in mucosal tissues. T cell specific ablation of SHIP1 expression in CD4CreSHIP1\n                    <jats:sup>flox\/flox<\/jats:sup>\n                    mice also results in Crohn\u2019s disease-like ileitis, but less severe than in their germline SHIP1\n                    <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    counterparts due to the absence of a SHIP1 deficient neutrophil compartment. Consequently CD4CreSHIP1\n                    <jats:sup>flox\/flox<\/jats:sup>\n                    mice live much longer than their SHIP1\n                    <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    counterparts. As Crohn\u2019s disease is associated with an increased risk of intestinal cancers in humans and that T cells are proposed to protect from occult malignancies, we hypothesized that CD4CreSHIP1\n                    <jats:sup>flox\/flox<\/jats:sup>\n                    mice would develop malignancies originating in the gut. Here we show that CD4CreSHIP1\n                    <jats:sup>flox\/flox<\/jats:sup>\n                    mice with ileitis develop spontaneous metastatic cancer originating in the small intestine, including widely disseminated histiocytic sarcoma and intestinal adenocarcinomas. Our findings demonstrate that T cells in the gut are essential to protect against occult intestinal cancers and that SHIP1 is essential for this function. These findings may aid our understanding of the increased susceptibility to intestinal cancer in IBD patients, and particularly since a significant subset of adult IBD patients have defective expression of SHIP1.\n                  <\/jats:p>","DOI":"10.1007\/s00018-026-06326-7","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T03:09:40Z","timestamp":1783393780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SHIP1 is required for T cell surveillance of occult malignancies"],"prefix":"10.1007","volume":"83","author":[{"given":"S.","family":"Fernandes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pedicone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Sudan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. W.","family":"Engelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4720-7135","authenticated-orcid":false,"given":"W. G.","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"6326_CR1","doi-asserted-by":"publisher","unstructured":"Krystal G (2000) Lipid phosphatases in the immune system [In Process Citation]. Semin Immunol 12(4):397\u2013403. [Online]. https:\/\/doi.org\/10.1006\/smim.2000.0222","DOI":"10.1006\/smim.2000.0222"},{"key":"6326_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.2010.05869.x","volume":"1217","author":"WG Kerr","year":"2011","unstructured":"Kerr WG (2011) Inhibitor and activator: dual functions for SHIP in immunity and cancer. Ann N Y Acad Sci 1217:1\u201317. https:\/\/doi.org\/10.1111\/j.1749-6632.2010.05869.x","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"6326_CR3","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1038\/mi.2014.32","volume":"7","author":"MY Park","year":"2014","unstructured":"Park MY et al (2014) Impaired T-cell survival promotes mucosal inflammatory disease in SHIP1-deficient mice. Mucosal Immunol 7(6):1429\u20131439. https:\/\/doi.org\/10.1038\/mi.2014.32","journal-title":"Mucosal Immunol"},{"key":"6326_CR4","doi-asserted-by":"publisher","unstructured":"Iyer S, Viernes DR, Chisholm JD, Margulies BS, Kerr WG (2014) SHIP1 regulates MSC numbers and their osteolineage commitment by limiting induction of the PI3K\/Akt\/beta-Catenin\/Id2 Axis. Stem Cells Dev. https:\/\/doi.org\/10.1089\/scd.2014.0122 (in Eng)","DOI":"10.1089\/scd.2014.0122"},{"key":"6326_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/nyas.12091","volume":"1280","author":"S Iyer","year":"2013","unstructured":"Iyer S, Margulies BS, Kerr WG (2013) Role of SHIP1 in bone biology. Ann N Y Acad Sci 1280:11\u20134. https:\/\/doi.org\/10.1111\/nyas.12091","journal-title":"Ann N Y Acad Sci"},{"key":"6326_CR6","doi-asserted-by":"publisher","unstructured":"Iyer S, Brooks R, Gumbleton M, Kerr WG (2014) SHIP1-expressing mesenchymal stem cell regulate hematopoietic stem cell homeostasis and lineage choice during aging. Stem cells and development. https:\/\/doi.org\/10.1089\/scd.2014.0501. Accessed\u00a019 December 2014","DOI":"10.1089\/scd.2014.0501"},{"issue":"2","key":"6326_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1136\/gut.2009.202283","volume":"60","author":"WG Kerr","year":"2011","unstructured":"Kerr WG, Park MY, Maubert M, Engelman RW (2011) SHIP deficiency causes Crohn\u2019s disease-like ileitis. Gut 60(2):177\u2013188. https:\/\/doi.org\/10.1136\/gut.2009.202283","journal-title":"Gut"},{"issue":"11","key":"6326_CR8","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1101\/gad.12.11.1610","volume":"12","author":"CD Helgason","year":"1998","unstructured":"Helgason CD et al (1998) Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev 12(11):1610\u20131620","journal-title":"Genes Dev"},{"issue":"5","key":"6326_CR9","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.4049\/jimmunol.178.5.2893","volume":"178","author":"KH Paraiso","year":"2007","unstructured":"Paraiso KH, Ghansah T, Costello A, Engelman RW, Kerr WG (2007) Induced SHIP deficiency expands myeloid regulatory cells and abrogates graft-versus-host disease. J Immunol 178(5):2893\u20132900. https:\/\/doi.org\/10.4049\/jimmunol.178.5.2893","journal-title":"J Immunol"},{"issue":"7","key":"6326_CR10","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1101\/gad.13.7.786","volume":"13","author":"Q Liu","year":"1999","unstructured":"Liu Q et al (1999) SHIP is a negative regulator of growth factor receptor-mediated PKB\/Akt activation and myeloid cell survival. Genes Dev 13(7):786\u2013791. https:\/\/doi.org\/10.1101\/gad.13.7.786","journal-title":"Genes Dev"},{"issue":"5022","key":"6326_CR11","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1136\/bmj.1.5022.779","volume":"1","author":"M Burnet","year":"1957","unstructured":"Burnet M (1957) Cancer; a biological approach. I. The processes of control. Br Med J 1(5022):779\u2013786. https:\/\/doi.org\/10.1136\/bmj.1.5022.779","journal-title":"Br Med J"},{"issue":"2","key":"6326_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","volume":"21","author":"GP Dunn","year":"2004","unstructured":"Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21(2):137\u2013148. https:\/\/doi.org\/10.1016\/j.immuni.2004.07.017","journal-title":"Immunity"},{"key":"6326_CR13","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1146\/annurev-immunol-042617-053402","volume":"37","author":"TN Schumacher","year":"2019","unstructured":"Schumacher TN, Scheper W, Kvistborg P (2019) Cancer neoantigens. Annu Rev Immunol 37:173\u2013200. https:\/\/doi.org\/10.1146\/annurev-immunol-042617-053402","journal-title":"Annu Rev Immunol"},{"issue":"6832","key":"6326_CR14","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/35074122","volume":"410","author":"V Shankaran","year":"2001","unstructured":"Shankaran V et al (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410(6832):1107\u20131111. https:\/\/doi.org\/10.1038\/35074122","journal-title":"Nature"},{"issue":"5","key":"6326_CR15","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1084\/jem.192.5.755","volume":"192","author":"MJ Smyth","year":"2000","unstructured":"Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA (2000) Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med 192(5):755\u2013760. https:\/\/doi.org\/10.1084\/jem.192.5.755","journal-title":"J Exp Med"},{"issue":"5","key":"6326_CR16","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1172\/JCI31405","volume":"117","author":"JB Swann","year":"2007","unstructured":"Swann JB, Smyth MJ (2007) Immune surveillance of tumors. J Clin Investig 117(5):1137\u20131146. https:\/\/doi.org\/10.1172\/JCI31405","journal-title":"J Clin Investig"},{"issue":"11","key":"6326_CR17","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1084\/jem.187.11.1825","volume":"187","author":"WF Davidson","year":"1998","unstructured":"Davidson WF, Giese T, Fredrickson TN (1998) Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J Exp Med 187(11):1825\u20131838. https:\/\/doi.org\/10.1084\/jem.187.11.1825","journal-title":"J Exp Med"},{"issue":"9","key":"6326_CR18","doi-asserted-by":"publisher","first-page":"5586","DOI":"10.4049\/jimmunol.175.9.5586","volume":"175","author":"N Zerafa","year":"2005","unstructured":"Zerafa N et al (2005) Cutting edge: TRAIL deficiency accelerates hematological malignancies. J Immunol 175(9):5586\u20135590. https:\/\/doi.org\/10.4049\/jimmunol.175.9.5586","journal-title":"J Immunol"},{"issue":"11 Pt 1","key":"6326_CR19","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1158\/1078-0432.CCR-06-0076","volume":"12","author":"H Takahashi","year":"2006","unstructured":"Takahashi H et al (2006) FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes. Clin Cancer Res 12(11 Pt 1):3265\u20133271. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0076","journal-title":"Clin Cancer Res"},{"issue":"3","key":"6326_CR20","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S0002-9440(10)63195-1","volume":"164","author":"S Wohlfart","year":"2004","unstructured":"Wohlfart S et al (2004) FAS (CD95) mutations are rare in gastric MALT lymphoma but occur more frequently in primary gastric diffuse large B-cell lymphoma. Am J Pathol 164(3):1081\u20131089. https:\/\/doi.org\/10.1016\/S0002-9440(10)63195-1","journal-title":"Am J Pathol"},{"key":"6326_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-2776(06)90001-7","volume":"90","author":"MJ Smyth","year":"2006","unstructured":"Smyth MJ, Dunn GP, Schreiber RD (2006) Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90:1\u201350. https:\/\/doi.org\/10.1016\/S0065-2776(06)90001-7","journal-title":"Adv Immunol"},{"issue":"2","key":"6326_CR22","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/(SICI)1521-4141(199902)29:02<602::AID-IMMU602>3.0.CO;2-Y","volume":"29","author":"E Zorn","year":"1999","unstructured":"Zorn E, Hercend T (1999) A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion. Eur J Immunol 29(2):602\u2013607. https:\/\/doi.org\/10.1002\/(SICI)1521-4141(199902)29:02%3c602::AID-IMMU602%3e3.0.CO;2-Y","journal-title":"Eur J Immunol"},{"issue":"2","key":"6326_CR23","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/(SICI)1521-4141(199902)29:02<592::AID-IMMU592>3.0.CO;2-2","volume":"29","author":"E Zorn","year":"1999","unstructured":"Zorn E, Hercend T (1999) A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. Eur J Immunol 29(2):592\u2013601. https:\/\/doi.org\/10.1002\/(SICI)1521-4141(199902)29:02%3c592::AID-IMMU592%3e3.0.CO;2-2","journal-title":"Eur J Immunol"},{"issue":"3","key":"6326_CR24","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1172\/JCI116278","volume":"91","author":"L Ferradini","year":"1993","unstructured":"Ferradini L et al (1993) Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion. J Clin Invest 91(3):1183\u20131190. https:\/\/doi.org\/10.1172\/JCI116278","journal-title":"J Clin Invest"},{"issue":"1-2","key":"6326_CR25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N (2015) Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160(1\u20132):48\u201361. https:\/\/doi.org\/10.1016\/j.cell.2014.12.033","journal-title":"Cell"},{"issue":"8","key":"6326_CR26","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723. https:\/\/doi.org\/10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"issue":"7","key":"6326_CR27","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1038\/ajg.2009.760","volume":"105","author":"N Pedersen","year":"2010","unstructured":"Pedersen N, Duricova D, Elkjaer M, Gamborg M, Munkholm P, Jess T (2010) Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol Meta-Anal Rev 105(7):1480\u20131487. https:\/\/doi.org\/10.1038\/ajg.2009.760. ((in Eng))","journal-title":"Am J Gastroenterol Meta-Anal Rev"},{"issue":"12","key":"6326_CR28","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1111\/j.1572-0241.2005.00287.x","volume":"100","author":"T Jess","year":"2005","unstructured":"Jess T, Gamborg M, Matzen P, Munkholm P, Sorensen TI (2005) Increased risk of intestinal cancer in Crohn\u2019s disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol Comp Study Meta-Anal Rev 100(12):2724\u20132729. https:\/\/doi.org\/10.1111\/j.1572-0241.2005.00287.x. ((in Eng))","journal-title":"Am J Gastroenterol Comp Study Meta-Anal Rev"},{"key":"6326_CR29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3389\/fimmu.2012.00107","volume":"3","author":"DC Rubin","year":"2012","unstructured":"Rubin DC, Shaker A, Levin MS (2012) Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer. Front Immunol 3:107. https:\/\/doi.org\/10.3389\/fimmu.2012.00107","journal-title":"Front Immunol"},{"key":"6326_CR30","unstructured":"Pohl C, Hombach A, Kruis W (2000) Chronic inflammatory bowel disease and cancer. Hepato-gastroenterol Rev 47(31):57\u201370. [Online].PMID: 10690586 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10690586"},{"issue":"1","key":"6326_CR31","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1136\/gutjnl-2020-322744","volume":"71","author":"X Sun","year":"2022","unstructured":"Sun X et al (2022) Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism. Gut 71(1):129\u2013147. https:\/\/doi.org\/10.1136\/gutjnl-2020-322744","journal-title":"Gut"},{"issue":"1","key":"6326_CR32","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1038\/s41467-025-59529-0","volume":"16","author":"R Trehan","year":"2025","unstructured":"Trehan R et al (2025) SPP1 + macrophages cause exhaustion of tumor-specific T cells in liver metastases. Nat Commun 16(1):4242. https:\/\/doi.org\/10.1038\/s41467-025-59529-0","journal-title":"Nat Commun"},{"issue":"6657","key":"6326_CR33","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1126\/science.ade2292","volume":"381","author":"R Bill","year":"2023","unstructured":"Bill R et al (2023) CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers. Science 381(6657):515\u2013524. https:\/\/doi.org\/10.1126\/science.ade2292","journal-title":"Science"},{"issue":"8023","key":"6326_CR34","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41586-024-07752-y","volume":"632","author":"H Sultan","year":"2024","unstructured":"Sultan H et al (2024) Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy. Nature 632(8023):182\u2013191. https:\/\/doi.org\/10.1038\/s41586-024-07752-y","journal-title":"Nature"},{"issue":"6","key":"6326_CR35","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/mi.2008.61","volume":"1","author":"B Kelsall","year":"2008","unstructured":"Kelsall B (2008) Recent progress in understanding the phenotype and function of intestinal dendritic cells and macrophages. Mucosal Immunol 1(6):460\u2013469. https:\/\/doi.org\/10.1038\/mi.2008.61","journal-title":"Mucosal Immunol"},{"issue":"1","key":"6326_CR36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41467-017-02424-0","volume":"9","author":"M Efremova","year":"2018","unstructured":"Efremova M et al (2018) Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution. Nat Commun 9(1):32. https:\/\/doi.org\/10.1038\/s41467-017-02424-0","journal-title":"Nat Commun"},{"issue":"13","key":"6326_CR37","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1182\/blood-2008-09-181164","volume":"113","author":"MM Collazo","year":"2009","unstructured":"Collazo MM et al (2009) SHIP limits immunoregulatory capacity in the T-cell compartment. Blood 113(13):2934\u20132944. https:\/\/doi.org\/10.1182\/blood-2008-09-181164","journal-title":"Blood"},{"issue":"7","key":"6326_CR38","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1002\/eji.201142092","volume":"42","author":"MM Collazo","year":"2012","unstructured":"Collazo MM, Paraiso KH, Park MY, Hazen AL, Kerr WG (2012) Lineage extrinsic and intrinsic control of immunoregulatory cell numbers by SHIP. Eur J Immunol 42(7):1785\u20131795. https:\/\/doi.org\/10.1002\/eji.201142092","journal-title":"Eur J Immunol"},{"issue":"8","key":"6326_CR39","doi-asserted-by":"publisher","first-page":"e0182308","DOI":"10.1371\/journal.pone.0182308","volume":"12","author":"R Somasundaram","year":"2017","unstructured":"Somasundaram R et al (2017) Analysis of SHIP1 expression and activity in Crohn\u2019s disease patients. PLoS One 12(8):e0182308. https:\/\/doi.org\/10.1371\/journal.pone.0182308","journal-title":"PLoS One"},{"key":"6326_CR40","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3389\/fimmu.2018.01100","volume":"9","author":"S Fernandes","year":"2018","unstructured":"Fernandes S et al (2018) SHIP1 deficiency in inflammatory bowel disease is associated with severe Crohn\u2019s disease and peripheral T cell reduction. Front Immunol 9:1100. https:\/\/doi.org\/10.3389\/fimmu.2018.01100","journal-title":"Front Immunol"},{"issue":"1","key":"6326_CR41","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2119\/molmed.2011.00178","volume":"18","author":"GM Fuhler","year":"2012","unstructured":"Fuhler GM et al (2012) Therapeutic potential of SH2 domain-containing inositol-5\u2019-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer. Mol Med 18(1):65\u201375. https:\/\/doi.org\/10.2119\/molmed.2011.00178","journal-title":"Mol Med"},{"issue":"6","key":"6326_CR42","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1182\/blood-2007-03-079699","volume":"110","author":"CJ Ong","year":"2007","unstructured":"Ong CJ et al (2007) Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells. Blood 110(6):1942\u20131949. https:\/\/doi.org\/10.1182\/blood-2007-03-079699","journal-title":"Blood"},{"issue":"4","key":"6326_CR43","doi-asserted-by":"publisher","first-page":"104170","DOI":"10.1016\/j.isci.2022.104170","volume":"25","author":"C Pedicone","year":"2022","unstructured":"Pedicone C et al (2022) Discovery of a novel SHIP1 agonist that promotes degradation of lipid-laden phagocytic cargo by microglia. iScience 25(4):104170. https:\/\/doi.org\/10.1016\/j.isci.2022.104170","journal-title":"iScience"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-026-06326-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-026-06326-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-026-06326-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:14:33Z","timestamp":1790810073000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-026-06326-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6326"],"URL":"https:\/\/doi.org\/10.1007\/s00018-026-06326-7","relation":{},"ISSN":["1420-9071"],"issn-type":[{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal studies were approved by the IACUC at the SUNY Upstate Medical University. No other ethical approvals are applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have been given the opportunity to review and edit the manuscript. All authors consent to publication of this data.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"352"}}